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ABSTRACT
Background: Recent studies reveal patients in clinical practice achieve viral suppression
less frequently than those in clinical trials1,2,3. Many variables influence the discrepancy,
including patient ethnicity. This study examines ethnic variability in the effectiveness and
tolerability of nelfinavir (NFV) and two nucleoside reverse transcriptase inhibitors (NsRTI)
in an urban HIV practice.
Methods: Retrospective chart review of all patients (N=504) seen at Bornemann Internal
Medicine (BIM) after April 1997 yielded 57 patients on NFV and two NsRTIs. Viral load
response was evaluated by percentage of patients <400 (copies/mL) by week 16 and
<50 (copies/mL) by week 24, of those with ultrasensitive (UQ) data. Other studies have
shown this to be predictive of long term durability 4,5.
Results: Patients analyzed (n=57) were: White = 18 (31.6%); Black = 22 (38.6%); Hispanic
= 17 (29.8%). Most patients were on BID NFV and: d4T/3TC (59.6%), AZT/3TC
(26.3%) and d4T/ddI (14.0%).
Table 1: Summary of Results
Ethnicity Evaluable <400 by Pts. with <50 by Mean Failure d/t
data week 16 UQ data week 24* CD4 non-compliance
White 13 (72.7%) 10 (76.9%) 6 5 (83.3%) +151 0
Black 17 (77.3%) 14(82.4%) 8 7 (87.5%) +206 1
Hispanic 11 (64.7%) 5(45.5%) 2 2 (100%) +119 3
*% of patients <50 by week 24 is based only on patients with UQ results.
Most discontinuations were not due to AEs. Only 5 of 37 discontinued because of intolerable
diarrhea.
Conclusions:  NFV and dual NsRTIs appears to be an effective and tolerable combination
regardless of ethnicity examined in this typical treatment setting. The higher prevalence of
noncompliance in Hispanic patients suggests the need for adherence interventions. The low
incidence of disabling diarrhea was encouraging; most patients were able to control diarrhea
with simple measures. Reasons for lower success rates in clinical practice vs. clinical trials
should be further examined.
The frequency with which patients achieve viral suppression in clinical practice is often
overestimated by the randomized, double blinded, placebo-controlled, clinical trial1,2,3.
Many variables influence decision making for provider and patient in the selection of a
proper regimen that is compatible with a patient’s lifestyle.  The fear of possible adverse
events as well as cultural and ethnic considerations also play a role.  A recent study has
shown that patients of different ethnicity within the same clinical practice differ in their
response to HAART2.  This study examines variability based on ethnicity in the effectiveness
and tolerability of Nelfinavir (NFV) and two nucleoside reverse transcriptase inhibitors
(NsRTIs) in an urban HIV practice.
• A retrospective chart review of all patients (N = 504) seen after April 1997 was conducted
at Bornemann Internal Medicine (BIM), an urban HIV clinic.
• Charts were abstracted for the following: viral load (VL), CD4, NFV regimen,
demographics, adverse events (AEs), and reasons for discontinuation.
• Viral load response was evaluated by the percentage of patients <400 by 16 weeks and
<50 by 24 weeks, of those with ultrasensitive (UQ) data.  Other studies have shown this
to be predictive of long-term success 4,5.
• Intent to Treat (ITT) (prescription written, no data = failure) and As Treated (AT) analyses
were performed.
• All ethnic subgroups in this study exhibited virologic success rates (ITT) much lower
than would be expected, based on previous data from clinical trials.
• The Black and White subgroups did not differ significantly in virologic and immunologic
response to HAART.  However, Hispanic patients had a lower mean CD4 response and
very poor virologic success rates (AT and ITT).  This may be due to a higher rate of
early discontinuation (<16 weeks) and noncompliance to the treatment plan.
• Black and Hispanic patients were less adherent with poor follow-up.  In particular, the
high rate of noncompliance in Hispanics (59%) on NFV regimens reflects a current trend
in the Hispanic population in our practice.  A few years ago, this population was more
adherent with a better response to HAART than other ethnic groups in our practice6.
Further investigation of this trend, including specific adherence interventions, is needed
for this population.
• Although diarrhea was the most common AE reported (affecting White patients twice
as frequently as Hispanic patients), it was easily controlled.  Only five patients discontinued
due to intolerable diarrhea.  Two of these five were also taking ddI.
• The majority of discontinuations were not due to AEs, but to external factors.  This
reminds providers, once more, of the importance of the patient’s psychosocial well-
being and lifestyle in the development and execution of a treatment plan.
• Clinical trials often exclude patients with past HAART experience or prior patterns of
noncompliance. Although this selection allows for a better representation of the performance
of a HAART regimen, the results do not necessarily correlate with the general patient
population in a clinical practice.  Based on our findings, we believe that lifestyle and
psychosocial factors play the most important role in this discrepancy.
• In summary, nelfinavir and two NsRTIs appears to be an effective and tolerable regimen
in patients with good compliance, regardless of race.  The discrepancies between success
rates in clinical practice vs. clinical trials should be further examined.
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• Chart Review yielded 57/504 patients on NFV (most BID) and two NsRTIs.  Most
patients were HAART experienced: 14/57 were treatment naïve; 25/57 were PI-
experienced; 11/57 were NVP experienced; 7 patients had dual/mono NsRTI experience.
• The demographics of BIM are as follows: 40% women, 14% gay men, and an equal
distribution among White, Black and Hispanic patients.
Figure 1: Study Patient Demographics and NFV Regimens (n=57)
Figure 3: Mean CD4 Response
Figure 2: Plasma HIV-1 RNA <400 (copies/mL) by week 16
and <50 (copies/mL) by week 24*
*Week 24 Results are based only on patients with ultrasensitive results.
** Only two Hispanic patients had UQ results.  Both were BLQ.
Table 2: Patient Compliance With Treatment Plan
White Black Hispanic
Poor Medication Adherence 0 4 7
      Subsequent Failure 0 1 3
Lost to Follow Up 2 4 3
      No labs 2 2 2
      No Return Visits 0 2 1
Table 4: Reasons for Discontinuation†
White Black Hispanic Total
Diarrhea 16.7% 4.5% 5.9% 8.8%
Jaundice 5.6% 9.1% 0.0% 5.3%
Other AE 5.6% 4.5% 11.8% 7.0%
Non-compliance 0.0% 9.1% 17.6% 8.8%
Illicit Drug Use 5.6% 9.1% 5.9% 7.0%
Change in ART 11.1% 9.1% 0.0% 7.0%
Virologic Failure 5.6% 0.0% 5.9% 3.5%
Other Non-AE 5.6% 18.2% 29.4% 19.3%
† 37 out of 57 (64.9%) patients discontinued.
Table 3: Adverse Events
White Black Hispanic Total
Diarrhea* 55.6% 36.4% 29.4% 40.4%
Nausea/Vomiting 27.8% 13.6% 11.8% 17.5%
Abdominal Pain 16.7% 0.0% 11.8% 8.8%
Other GI 0.0% 27.3% 11.8% 8.8%
Headache 11.1% 18.2% 29.4% 19.3%
Fatigue 11.1% 18.2% 17.6% 15.8%
Neuropathy** 11.1% 22.7% 11.8% 15.8%
Lipodystrophy 11.1% 13.6% 0.0% 8.8%
Other Non-GI 11.1% 18.2% 5.9% 17.5%
No AEs 16.7% 18.2% 17.6% 17.5%
* Four of seven patients in d4T/ddI subgroup reported diarrhea.
























































<400 by week 16



























d4T/3TC = 10 (59%)
AZT/3TC = 5 (29%)
d4T/ddI = 2 (12%)
Hispanic
30%
d4T/3TC = 10 (55%)
AZT/3TC = 5 (28%)
d4T/ddI = 3 (17%)
d4T/3TC = 14 (64%)
AZT/3TC = 5 (22%)
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